Clinigen (LSE:CLIN)
Historical Stock Chart

From Apr 2019 to Apr 2024

TIDMCLIN

RNS Number : 8046T

Clinigen Group plc

13 January 2017

13 January 2017

Change of Joint Broker

Clinigen Group plc (AIM: CLIN, 'Clinigen' or the 'Group'), the global pharmaceutical and services group, announces that it has appointed RBC Capital Markets to act as its Joint Broker with immediate effect. Numis Securities Limited continues to act as Nominated Adviser and Joint Broker to the Company.

-Ends-

Contact Details

 
 Clinigen Group plc                       Tel: +44 (0) 1283 
                                           495 010 
 Shaun Chilton, Group Chief 
  Executive Officer 
  Martin Abell, Group Chief Financial 
  Officer 
  Matt Parrish, Head of Investor 
  Relations 
 
 Numis Securities Limited                 Tel: +44 (0) 20 
                                           7260 1000 
 Michael Meade / Freddie Barnfield 
  (Nominated Adviser) 
  James Black / Tom Ballard 
  (Corporate Broking) 
 
 RBC Capital Markets                      Tel: +44 (0) 20 
                                           7653 4000 
 Marcus Jackson / Elliot Thomas 
  / Jack Wood 
 
 Instinctif Partners (media               Tel: +44 (0) 20 
  relations)                               7457 2020 
 Adrian Duffield / Melanie Toyne-Sewell   Email: clinigen@instinctif.com 
 

About Clinigen Group

Clinigen Group plc (AIM: CLIN) is a global pharmaceutical and services company with a unique combination of businesses focused on providing access to medicines. Its mission is to deliver the right medicine to the right patient at the right time.

The Group consists of five synergistic businesses focused in three areas of global medicine supply; clinical trial, unlicensed and licensed medicines.

Clinigen Clinical Trial Services is the global market leader in the management and supply of commercial medicines for clinical trials.

The Group is also the trusted global leader in ethically sourcing and supplying unlicensed medicines to hospital pharmacists and physicians for patients with a high unmet need, through three of its divisions: Idis Managed Access runs early access programs for innovative new medicines. Idis Global Access and Link Healthcare work directly with healthcare professionals to enable compliant access to unlicensed medicines on a global basis and niche essential licensed and generic medicines across Australasia, Africa and Asia (AAA region).

Clinigen Specialty Pharmaceuticals acquires global rights, revitalises and markets its own portfolio of niche hospital commercial products.

For more information, please visit www.clinigengroup.com

This information is provided by RNS

The company news service from the London Stock Exchange

END

APPBMMBTMBABBRR

(END) Dow Jones Newswires

January 13, 2017 05:00 ET (10:00 GMT)